Invention Grant
- Patent Title: Conditional rodent Acvr1 mutant gene
-
Application No.: US16175762Application Date: 2018-10-30
-
Publication No.: US10531648B2Publication Date: 2020-01-14
- Inventor: Aris N. Economides , Sarah Jane Hatsell
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: US NY Tarrytown
- Agency: Alston & Bird LLP
- Agent Brian A. Cocca
- Main IPC: A01K67/027
- IPC: A01K67/027 ; C07H21/02 ; C07K14/71 ; C12N15/85

Abstract:
A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.
Public/Granted literature
- US20190053473A1 Rodents With Conditional ACVR1 Mutant Alleles Public/Granted day:2019-02-21
Information query